再生障碍性贫血患者的血清血小板生成素水平

Serum thrombopoietin levels in patients with aplastic anaemia.

作者信息

Marsh J C, Gibson F M, Prue R L, Bowen A, Dunn V T, Hornkohl A C, Nichol J L, Gordon-Smith E C

机构信息

Department of Cellular and Molecular Sciences, St George's Hospital Medical School, London, U.K.

出版信息

Br J Haematol. 1996 Dec;95(4):605-10. doi: 10.1046/j.1365-2141.1996.d01-1966.x.

DOI:10.1046/j.1365-2141.1996.d01-1966.x

PMID:8982033

Abstract

Endogenous serum thrombopoietin (TPO) levels were measured in 31 patients with aplastic anaemia (AA) using an enzyme immunoassay with a sensitivity of 20 pg/ ml. The median platelet count for all AA patients was 30 +/- 29 x 10(9)/l (range 5-102) compared with a median of 284 +/- 59 x 10(9)/l (range 148-538) for normal controls. Serum TPO levels were significantly elevated in all patients compared with normals (1706 +/- 1114.2, range 375-5000 v 78 +/- 54, range 16.5-312.9, P < 0.0001). There was no correlation between serum TPO levels and the degree of thrombocytopenia in AA patients, but TPO levels were significantly higher in patients who were platelet transfusion dependent than in patients who were transfusion independent (P < 0.01). There was a trend for higher TPO levels in patients with severe AA compared with non-severe AA patients. Clinical trials of TPO and a related truncated, pegylated molecule, megakaryocyte growth and development factor (PEG-rHuMGDF), are awaited to determine whether treatment with these drugs will result in increased platelet counts in patients with AA.

摘要

采用灵敏度为20 pg/ml的酶免疫测定法，对31例再生障碍性贫血（AA）患者的内源性血清血小板生成素（TPO）水平进行了检测。所有AA患者的血小板计数中位数为30±29×10⁹/l（范围5 - 102），而正常对照的中位数为284±59×10⁹/l（范围148 - 538）。与正常对照相比，所有患者的血清TPO水平均显著升高（1706±1114.2，范围375 - 5000对78±54，范围16.5 - 312.9，P < 0.0001）。AA患者的血清TPO水平与血小板减少程度之间无相关性，但血小板输注依赖患者的TPO水平显著高于非依赖患者（P < 0.01）。与非重度AA患者相比，重度AA患者的TPO水平有升高趋势。TPO及相关截短的聚乙二醇化分子巨核细胞生长发育因子（PEG-rHuMGDF）的临床试验有待开展，以确定这些药物治疗是否会使AA患者的血小板计数增加。